Peptide library
ATN-161
Your guide to this compound.
Dose context
Early human oncology trial; no approved treatment regimen supplied.
Study context only: 0.1–16 mg/kg in sequential cohorts, infused over 10 minutes three times weekly. This was dose escalation, not an established treatment regimen.
How to read this information
Catalog ranges can describe approved labeling, clinical research or unverified reports. They are not interchangeable and do not select a personal dose.
Half-life
The phase 1 intravenous study reported a 3.2–5.0-hour half-life. This value cannot be assigned to subcutaneous, oral or retail formulations.
Species, route and formulation matter. Half-life does not define a safe dosing interval.
Routes and frequency in the catalog
Storage
No product-specific stability specification was verified. A generic refrigeration period cannot establish potency, sterility or a beyond-use date.
Generic storage notes cannot establish a beyond-use date or sterility for a particular vial.
Preparation and reconstitution
No validated human-use preparation instructions are supplied in this snapshot.